EC5026

• Description :

  EC5026 (BPN-19186) is a first-in-class, non-opioid and orally active soluble Epoxide Hydrolase (sEH) inhibitor. EC5026 shows efficacy for inflammatory and neuropathic pain[1].

• Product Name Alternative :

  BPN-19186

• UNSPSC :

  12352005

• Hazard Statement :

  H301

• Target :

  Epoxide Hydrolase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/ec5026.html

• Purity :

  98.13

• Solubility :

  DMSO : ≥ 250 mg/mL

• Smiles :

  O=C(NC1CCN(C([C@@H](C)CC)=O)CC1)NC2=CC=C(OC(F)(F)F)C(F)=C2

• Molecular Formula :

  C18H23F4N3O3

• Molecular Weight :

  405.39

• Precautions :

  H301

• References & Citations :

  [1]EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain.2019.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [1809885-32-2]